What is the analyst consensus rating for DNLI?

The analyst consensus rating for DNLI is "Buy" based on 17 analyst recommendations.

What is the average price target for DNLI?

The average 12-month price target for DNLI is $37.50, representing an upside of 51.4% from the current price of $24.77.

What do analyst ratings mean?

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

What is a price target?

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.

Denali Therapeutics Inc. (DNLI) Forecast: Analyst Ratings & Targets

Latest DNLI Analyst Ratings & Recommendations

Recent analyst recommendations with rating changes and price target updates (last 90 days)

Date	Analyst	Firm	Action	Rating	Price Target
May 26, 2026	Sean Laaman	Morgan Stanley	Maintains	Buy	$40.00 → $35.00 -5.00 (-12.5%)
May 22, 2026	Andrew Fein	HC Wainwright	Maintains	Buy	$42.00
May 22, 2026	Myles Minter	William Blair	Maintains	Buy	-
May 22, 2026	David Hoang	Deutsche Bank	Maintains	Buy	$35.00 → $31.00 -4.00 (-11.4%)
May 22, 2026	Unknown Analyst	Jefferies	Maintains	Buy	$40.00
May 22, 2026	Tazeen Ahmad	BofA Securities	Maintains	Buy	-
May 11, 2026	Thomas Shrader	BTIG	Maintains	Buy	$39.00
May 11, 2026	Jay Olson	Oppenheimer	Maintains	Buy	$35.00 → $40.00 +5.00 (14.3%)
May 8, 2026	Laura Chico	Wedbush	Maintains	Buy	$25.00 → $23.00 -2.00 (-8.0%)
May 8, 2026	Joseph Thome	TD Cowen	Maintains	Buy	-
Apr 22, 2026	Marc Goodman	Leerink Partners	Maintains	Buy	$40.00 → $35.00 -5.00 (-12.5%)
Apr 7, 2026	Joel Beatty	Baird	Maintains	Buy	$32.00 → $34.00 +2.00 (6.3%)
Mar 29, 2026	Paul Matteis	Stifel Nicolaus	Maintains	Buy	$34.00 → $41.00 +7.00 (20.6%)
Mar 26, 2026	Andrew S. Fein	HC Wainwright	Maintains	Strong Buy	$32.00 → $42.00 +10.00 (31.3%)
Mar 26, 2026	Paul Mattels	Stifel	Maintains	Strong Buy	$34.00 → $41.00 +7.00 (20.6%)
Mar 26, 2026	Salveen Richter	Goldman Sachs	Maintains	Strong Buy	$35.00 → $40.00 +5.00 (14.3%)
Mar 26, 2026	Joel Beatty	Baird	Maintains	Buy	$29.00 → $32.00 +3.00 (10.3%)
Mar 26, 2026	Matthew Harrison	Morgan Stanley	Maintains	Buy	$40.00 → $42.00 +2.00 (5.0%)

Sean Laaman

Morgan Stanley

BuyMaintains

$40.00 → $35.00

May 26

Andrew Fein

HC Wainwright

BuyMaintains

$42.00

May 22

Myles Minter

William Blair

BuyMaintains

May 22

David Hoang

Deutsche Bank

BuyMaintains

$35.00 → $31.00

May 22

Unknown Analyst

Jefferies

BuyMaintains

$40.00

May 22

Tazeen Ahmad

BofA Securities

BuyMaintains

May 22

Thomas Shrader

BTIG

BuyMaintains

$39.00

May 11

Jay Olson

Oppenheimer

BuyMaintains

$35.00 → $40.00

May 11

Laura Chico

Wedbush

BuyMaintains

$25.00 → $23.00

May 8

Joseph Thome

TD Cowen

BuyMaintains

May 8

Marc Goodman

Leerink Partners

BuyMaintains

$40.00 → $35.00

Apr 22

Joel Beatty

Baird

BuyMaintains

$32.00 → $34.00

Apr 7

Paul Matteis

Stifel Nicolaus

BuyMaintains

$34.00 → $41.00

Mar 29

Andrew S. Fein

HC Wainwright

Strong BuyMaintains

$32.00 → $42.00

Mar 26

Paul Mattels

Stifel

Strong BuyMaintains

$34.00 → $41.00

Mar 26

Salveen Richter

Goldman Sachs

Strong BuyMaintains

$35.00 → $40.00

Mar 26

Joel Beatty

Baird

BuyMaintains

$29.00 → $32.00

Mar 26

Matthew Harrison

Morgan Stanley

BuyMaintains

$40.00 → $42.00

Mar 26

Denali Therapeutics Inc. (DNLI) Analyst Forecast

Analyst Consensus Rating

Consensus Rating

Average Price Target

Latest DNLI Analyst Ratings & Recommendations

Frequently Asked Questions